CHAMP1-related disorders: pathomechanisms triggered by different genomic alterations define distinct nosological categories.


Journal

European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 20 09 2022
accepted: 25 01 2023
revised: 17 01 2023
pmc-release: 01 06 2024
medline: 12 6 2023
pubmed: 17 2 2023
entrez: 16 2 2023
Statut: ppublish

Résumé

Loss-of-function variants in CHAMP1 were recently described as cause of a neurodevelopmental disorder characterized by intellectual disability (ID), autism, and distinctive facial characteristics. By exome sequencing (ES), we identified a truncating variant in CHAMP1, c.1858A > T (p.Lys620*), in a patient who exhibited a similar phenotype of severe ID and dysmorphisms. Whether haploinsufficiency or a dominant negative effect is the underlying pathomechanism in these cases is a question that still needs to be addressed. By array-CGH, we detected a 194 kb deletion in 13q34 encompassing CHAMP1, CDC16 and UPF3, in another patient who presented with borderline neurodevelopmental impairment and with no dysmorphisms. In a further patient suffering from early onset refractory seizures, we detected by ES a missense variant in CHAMP1, c.67 G > A (p.Gly23Ser). Genomic abnormalities were all de novo in our patients. We reviewed the clinical and the genetic data of patients reported in the literature with: loss-of-function variants in CHAMP1 (total 40); chromosome 13q34 deletions ranging from 1.1 to 4 Mb (total 7) and of the unique patient with a missense variant. We could infer that loss-of-function variants in CHAMP1 cause a homogeneous phenotype with severe ID, autism spectrum disorders (ASD) and highly distinctive facial characteristics through a dominant negative effect. CHAMP1 haploinsufficiency results in borderline ID with negligible consequences on the quality of life. Missense variants give rise to a severe epileptic encephalopathy through gain-of-function mechanism, most likely. We tentatively define for the first time distinct categories among the CHAMP1-related disorder on the basis of pathomechanisms.

Identifiants

pubmed: 36797464
doi: 10.1038/s41431-023-01305-z
pii: 10.1038/s41431-023-01305-z
pmc: PMC10250409
doi:

Substances chimiques

CHAMP1 protein, human 0
Chromosomal Proteins, Non-Histone 0
Phosphoproteins 0

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

648-653

Subventions

Organisme : Fondazione Telethon (Telethon Foundation)
ID : GSP15001
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 779257

Investigateurs

Annalaura Torella (A)
Gerarda Cappuccio (G)
Francesco Musacchia (F)
Margherita Mutarelli (M)
Diego Carrella (D)
Giuseppina Vitiello (G)
Giancarlo Parenti (G)
Vincenzo Leuzzi (V)
Angelo Selicorni (A)
Silvia Maitz (S)
Nicola Brunetti-Pierri (N)
Sandro Banfi (S)
Martino Montomoli (M)
Donatella Milani (D)
Corrado Romano (C)
Albina Tummolo (A)
Daniele De Brasi (D)
Antonietta Coppola (A)
Claudia Santoro (C)

Informations de copyright

© 2023. The Author(s), under exclusive licence to European Society of Human Genetics.

Références

Mol Genet Genomic Med. 2017 Jul 12;5(5):585-591
pubmed: 28944241
Hum Mol Genet. 2022 Aug 17;31(15):2582-2594
pubmed: 35271727
Am J Hum Genet. 2015 Sep 3;97(3):493-500
pubmed: 26340335
Hum Mutat. 2016 Apr;37(4):354-8
pubmed: 26751395
Hum Genet. 2019 Oct;138(10):1145-1153
pubmed: 31321490
Cold Spring Harb Mol Case Stud. 2021 Aug 2;7(4):
pubmed: 34021018
Cold Spring Harb Mol Case Stud. 2016 Jan;2(1):a000661
pubmed: 27148580
Gene. 2013 Oct 1;528(1):51-4
pubmed: 23639964
Mol Genet Metab. 2016 May;118(1):60-3
pubmed: 27067448

Auteurs

Simona Amenta (S)

Department of Biomedical Sciences, Clinical Genetics Service, Azienda Ospedaliero-Universitaria di Sassari, Sassari, Italy.

Giuseppe Marangi (G)

Genomic Medicine, Policlinico Universitario "A. Gemelli" Foundation IRCCS, Rome, Italy.
Department of Life Sciences and Public Health, Catholic University, Rome, Italy.

Daniela Orteschi (D)

Genomic Medicine, Policlinico Universitario "A. Gemelli" Foundation IRCCS, Rome, Italy.

Silvia Frangella (S)

Genomic Medicine, Policlinico Universitario "A. Gemelli" Foundation IRCCS, Rome, Italy.
Department of Life Sciences and Public Health, Catholic University, Rome, Italy.

Fiorella Gurrieri (F)

Unit of Medical and Functional Genetics, University Campus Bio-Medico, Rome, Italy.

Elisa Paccagnella (E)

Department of Medical-Surgical Sciences and Biotechnologies, La Sapienza University, Rome, Italy.

Marcello Scala (M)

Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.
Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.

Ferruccio Romano (F)

Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy.
Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.

Valeria Capra (V)

Medical Genetics Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy.

Vincenzo Nigro (V)

Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
Telethon Institute of Genetics and Medicine, Pozzuoli, Italy.

Marcella Zollino (M)

Genomic Medicine, Policlinico Universitario "A. Gemelli" Foundation IRCCS, Rome, Italy. marcella.zollino@unicatt.it.
Department of Life Sciences and Public Health, Catholic University, Rome, Italy. marcella.zollino@unicatt.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH